EGFR and non-small cell lung carcinoma: In the MARIPOSA Trial [32], amivantamab–lazertinib led to a superior PFS and median response duration compared with the osimertinib group in patients with previously untreated or osimertinib-pretreated EGFR-mutated advanced NSCLC.